Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel
NEJM 342:1773-1777,1824, Bennett,C.L.,et al, 2000
Thrombotic Thrombocytopenic Purpura Associated with Ticlopidine Use,A Report of 3 Cases and Review of the Literature
Arch Int Med 159:311-314, Chen,D.K.,et al,, 1999
Thrombotic Thrombocytopenic Purpura Assoc with Ticlopidine, Review of 10 Cases
Ann Int Med 128:541-544, Bennett,C.L.,et al, 1998
Clinicopath Conf
Leucocytoclastic Vasculitis, Due to Staphylococcal Protein A Column Therapy with CVA, Case 35-1994,, EJM1:792-800,1994., 1994
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromyelitis Optica: Evaluation of 871 Attacks and 1,153 Treatment Courses
Ann Neurol 79:206-216,204, Kleiter, I.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Morvan Syndrome: Clinical and Serological Observations in 29 Cases
Ann Neurol 72:241-255, Irani, S.R.,et al, 2012
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Transverse Myelitis
NEJM 363:564-572, Frohman,E.M. &Wingerchuk,D.M., 2010
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Pathophysiology of Thrombotic Thrombocytopenic Purpura
Int J Hematol 91:1-30, Tsai, H.M., 2010
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Voltage-gated Potassium Channel-associated Limbic Encepahlitis in the West of Scotland:Case Reports and Literature Review
Scott Med J 54:27-31, Reid,J.M.,et al, 2009
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Non-Paraneoplastic Limbic Encephalitis Associated with Anti-Glutamic Acid Decarboxylase Antibodies
J Neuroimmunol 199:155-159, Mata,S.,et al, 2008
Plasma Exchange for Anti GAD Associated Non Paraneoplastic Limbic Encephalitis
Transfus Apher Sci 39:229-233, Mazzi,G.,et al, 2008
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Assessment of Plasmapheresis
Report of the Therapeutics and Technology Assessment Subcommittee of the AAN, Neurol 47:840-8431996., , 1996
Chronic Inflammatory Demyelinating Polyradiculoneuropathy:Unusual Clinical Features and Therapeutic Responses
Neurol 46:1206-1212, Midroni,G.&Dyck,P.J., 1996
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Acute Neuromuscular Respiratory Paralysis
JNNP 56:334-343, Hughes,R.A.C.&Bihari,D., 1993
Intensive Management and Treatment of Severe Guillain-Barre Syndrome
Crit Care Med 21:433-446, Hund,E.F.,et al, 1993
The Use of Immunosuppressive Agents in the Treatment of Multiple Sclerosis:A Critical Review
Neurol 41:980-985, Goodin,D.S., 1991
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
The Utility of Therapeutic Plasmapheresis for Neurological Disorders
JAMA 256:1333-1337, , 1986
Plasmapheresis Therapeutic or Experimental Procedure
Arch Neurol 41:647-653, Dau,P.C., 1984
Plasma Exchange in Neurologic Diseases
Arch Neurol 41:654-657, Lisak,R.P., 1984
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Reversible Gait Ataxia
Neurol 88:e145-e149, Abkur, T.M. & Bede, P., 2017
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Comparison of IVIg and PLEX in patients with myasthenia gravis
Neurol 76:2017-2023, Barth, D.,et al, 2011
N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011
Autoimmune Limbic Encephalitis with GAD Antibodies
The Neurohospitalist 1:178-181, Finelli, P.F., 2011